about
Early phase clinical trials to identify optimal dosing and safetyThe pancreas cancer microenvironmentAnti-tumour efficacy of capecitabine in a genetically engineered mouse model of pancreatic cancerChemotherapy vs supportive care alone for relapsed gastric, gastroesophageal junction, and oesophageal adenocarcinoma: a meta-analysis of patient-level data.Gemcitabine diphosphate choline is a major metabolite linked to the Kennedy pathway in pancreatic cancer models in vivo.Direct histological processing of EUS biopsies enables rapid molecular biomarker analysis for interventional pancreatic cancer trials.A novel method for quantification of gemcitabine and its metabolites 2',2'-difluorodeoxyuridine and gemcitabine triphosphate in tumour tissue by LC-MS/MS: comparison with (19)F NMR spectroscopy.Crosstalk between the canonical NF-κB and Notch signaling pathways inhibits Pparγ expression and promotes pancreatic cancer progression in mice.Gamma secretase inhibition promotes hypoxic necrosis in mouse pancreatic ductal adenocarcinomaChoice of Starting Dose for Biopharmaceuticals in First-in-Human Phase I Cancer Clinical Trials.Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer.nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer.Small cell carcinoma of the urinary bladder: a 15-year retrospective review of treatment and survival in the Anglian Cancer Network.Stromal biology and therapy in pancreatic cancer.The International Core Literature Consensus (ICLC): an alternative curriculum for Oncologists.Predictive in vivo animal models and translation to clinical trials.Trimodality therapy and definitive chemoradiotherapy for esophageal cancer: a single-center experience and review of the literature.E-Mail Communication Practices and Preferences Among Patients and Providers in a Large Comprehensive Cancer Center.FOLFIRINOX for advanced pancreatic cancer: the Princess Margaret Cancer Centre experience.Determinants of the recommended phase 2 dose of molecular targeted agents.A phase 2 study of vatalanib in metastatic melanoma patients.Exome-Wide Association Study of Pancreatic Cancer Risk.Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial.A novel Phase I/IIa design for early phase oncology studies and its application in the evaluation of MK-0752 in pancreatic cancer.Signaling pathway screening platforms are an efficient approach to identify therapeutic targets in cancers that lack known driver mutations: a case report for a cancer of unknown primary origin.Reply to K.K. Sahu et alCathepsin B promotes the progression of pancreatic ductal adenocarcinoma in miceMolecular characterisation and liquid biomarkers in Carcinoma of Unknown Primary (CUP): taking the ‘U’ out of ‘CUP’Novel Early Phase Clinical Trial Design in OncologyEndothelin-1 and endothelin B receptor expression in pancreatic adenocarcinomaAssessing the role of the EGF receptor in the development and progression of pancreatic cancerK‐Ras‐Driven Pancreatic Cancer Mouse Model for Anticancer Inhibitor AnalysesUtility of ctDNA to support patient selection for early phase clinical trials: the TARGET studyCumulative Antibiotic Use Significantly Decreases Efficacy of Checkpoint Inhibitors in Patients with Advanced Cancer
P50
Q26865076-EE2CA1DE-B32F-4568-89E0-8CD90E0454C4Q27026705-98CD046C-B49E-46E5-98F0-CCC4C9F31636Q28534413-F2121536-4BC4-4913-B2DE-E1582427D651Q31046335-494DCB8D-BFC1-4BC3-8B81-4BC0E7177186Q33918107-29B6D3DB-9A24-4371-B83C-E3550E0CA22EQ34225944-8C10A773-3E28-4418-BCB1-006B92793717Q35549387-1BC4FA5B-64BD-4D00-8752-641AABFAB16EQ35578568-53F6520A-9C41-4FE6-B01A-11EEB2F5CDC4Q35825974-0C549E08-ACC1-4CD0-967E-67B5EAEA4F15Q36064870-2A215D09-6D12-449F-BF55-2977AFAF24FEQ36550798-AD31183C-886A-4E53-AB44-7F163ADED529Q36901035-3A328085-9A8F-465B-B56F-0918FCF27F77Q37348345-9B9F7722-A070-4698-AF64-0021D25ECE1FQ37802090-D0A61F06-EE72-4964-BF8A-19BB84BE192DQ37885278-3654EC02-FF14-4567-8E15-37EA9BE2F680Q38001718-FA4C4E7E-4A84-45F5-923F-CFADB9627D08Q38215125-EF6D9EBF-40BD-4BDD-A9A7-B46AF6669FF7Q38879798-67486CFF-5184-4A09-8AD6-122C3E91C5F8Q38910968-49C863D8-FEBF-46DE-8CB2-D2B9FDE85708Q39128248-1FB0AB44-56FE-4BCD-8F6C-805A6DCE4166Q42923862-EE5EB717-3CCD-4940-8EF4-8613EC1E69ECQ47710148-9B73459F-8E51-496E-8F49-CDF0C75EE862Q48117450-477F6FEB-7409-4C86-8D60-A06097B5118BQ51383258-417CF766-E00A-4544-AE81-378FD69A9F78Q55363725-1CDDEFCC-8FA4-429F-9FDD-50C00F0AE987Q58819284-DB11C827-5C95-4045-823C-B35DFAB6AF3DQ63283423-12A33B03-96D0-4F1D-A4E4-49BABE55E61FQ63366116-2BD8BD61-04FB-41AF-AB22-98C19FA0AC2EQ63366117-7531EC69-DE62-40C8-B681-BB83BFF84A79Q63366119-1850929B-4A1F-4FE6-987A-B34564AFC7D1Q63366121-6199226B-765D-4734-91EF-302BFB73962CQ63366123-8622B2C7-82A4-41A0-AE9E-BE9FD23F6EBEQ90215699-08889443-1A19-4505-96D5-19501392824FQ91775923-D79C3ACC-6A56-4DC1-9498-ECE9309160A6
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0003-2606-1082
@en
name
Natalie Cook
@ast
Natalie Cook
@en
Natalie Cook
@es
Natalie Cook
@nl
type
label
Natalie Cook
@ast
Natalie Cook
@en
Natalie Cook
@es
Natalie Cook
@nl
prefLabel
Natalie Cook
@ast
Natalie Cook
@en
Natalie Cook
@es
Natalie Cook
@nl
P1153
P106
P1153
24830417500
57190282297
57196009879
P21
P31
P496
0000-0003-2606-1082